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Abstract 
Objective: We assessed the lesion detectability of low dose diagnostic 
123I-metaiodobenzylguanidine (MIBG) whole body scans obtained at 6 and 24 
hours compared with post-treatment 131I-MIBG whole body scans in 
malignant pheochromocytoma and paraganglioma. 
Methods: Scintigrams obtained in 15 patients with malignant 
pheochromocytoma and paraganglioma were retrospectively analyzed. 
Diagnostic scans were performed with 111MBq of 123I-MIBG. Therapeutic 
doses of 131I-MIBG (5.55 to 7.40GBq) were administrated and whole body 
scans were obtained at 2 to 5 days after 131I-MIBG administrations. We 
compared the number of lesions and the lesion-to-referent count ratios at 6 
hours and 24 hours of 123I-MIBG and at 2 to 5 days of 131I-MIBG. 
Results: In comparison with the 6-hour images of 123I-MIBG, the 24-hour 
images of 123I-MIBG could detect more lesions in 8 patients. Post-treatment 
131I-MIBG scans revealed new lesions in 8 patients compared with the 
24-hour images of 123I-MIBG. The lesion-to-referent count ratios at 6 hours 
and 24 hours of 123I-MIBG and at 3 days of 131I-MIBG were increasing at 
later scanning time. There were significant differences in the 
lesion-to-referent count ratios between 6 hours and 24 hours of 123I-MIBG (p 
= 0.031), 6 hours of 123I-MIBG and 3 days of 131I-MIBG (p = 0.020), and 24 
hours of 123I-MIBG and 3 days of 131I-MIBG (p = 0.018). 
Conclusions: Low dose diagnostic 123I-MIBG whole body scan is inferior to 
post-treatment 131I-MIBG whole body scan in malignant pheochromocytoma 
and paraganglioma. Considering the scan timing of 123I-MIBG, 6-hour 
images might have no superiority compared with 24-hour images. 
 
Keywords: pheochromocytoma; paraganglioma; MIBG; 123I; 131I. 
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Introduction 
Metaiodobenzylguanidine (MIBG), which can be labeled with either 131I or 
123I, mimics the neurotransmitter norepinephrine and specifically targets 
malignant cells of the sympathetic nervous system [1, 2]. Since 131I-MIBG 
was reported to visualize tumors of the adrenal medulla in the early 1980s [3, 
4], 131I-MIBG and 123I-MIBG have been widely used for detecting lesions in 
patients with malignant neuroendocrine tumors, such as malignant 
pheochromocytomas, malignant paragangliomas, medullary thyroid 
carcinomas, carcinoid tumors and neuroblastomas [5-9]. 123I-MIBG has 
superiority over 131I-MIBG with diagnostic use, because the γ-ray energy of 
123I (159keV) befits the image quality and lesion detectability for 
scintigraphy compared with that of 131I (364keV) [10-12]. Moreover, 123I 
offers favorable dosimetry compared to 131I, because of their γ-ray energy and 
their half-life (123I: 13.13 hours, 131I: 8.04 days) [13]. 
 
It has been reported that other imaging modalities may be useful in 
detecting nuroendocrine tumors. Many articles compared 123I-MIBG with 
18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) 
or 18F-FDG PET/computed tomography (CT) have been reported. These 
articles did not show good concordance [14-17], therefore 123I-MIBG and 
18F-FDG PET would possess complementary roles. 
18F-3,4-dihydroxy-phenylalanine PET, 18F-fluorodopamone PET and 
68Ga-DOTA peptides PET might be preferred in comparison with 123I-MIBG 
[17, 18]. However, the evidence for these radiopharmaceuticals is insufficient 
and these have not become widely used yet. 
 
As a prelude to 131I-MIBG therapy, 123I-MIBG scintigraphy is essential for 
the confirmation of MIBG accumulation to lesions. After 131I-MIBG therapy, 
post-treatment 131I-MIBG scintigraphy is routinely used to assess tumor 
uptake rather than lesion detectability. Lesional detectability of 123I-MIBG 
scans was not always the same as that of post-treatment 131I-MIBG scans. 
Campbell et al. [19] reported a case in which the post-treatment 131I-MIBG 
image depicted more metastatic lesions compared with the 131I-MIBG 
diagnostic scan and 123I-MIBG scan in a patient with malignant 
pheochromocytoma. Fukuoka et al. [20] demonstrated that 3-day images of 
post-therapeutic 131I-MIBG had superiority over 6-hour images of low dose 
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diagnostic 123I-MIBG in patients with malignant pheochromocytomas, 
malignant paragangliomas and neuroblastomas. Considering the 
lesion-to-background count ratios of 123I-MIBG images, 6-hour images would 
be inferior to 24-hour images in detecting lesions. To our knowledge, most 
previous studies evaluated scintigrams only by visual assessment, and there 
is no literature that reports the quantitative analysis of the image based on 
the count density and the lesion detectability between 6 and 24-hour scans of 
diagnostic 123I-MIBG and post-therapeutic 131I-MIBG scans. 
 
In this study, we compared low dose diagnostic 123I-MIBG scans obtained at 6 
hours, at 24 hours, and post-treatment 131I-MIBG scans by visual and 
quantitative methods in detecting lesions of malignant pheochromocytoma 
and paraganglioma, and then evaluated the validity of the dose and the 
scanning time of 123I-MIBG scintigraphy. 
 
Methods 
Patients 
We studied 15 consecutive patients who underwent first 131I-MIBG therapy 
for adult malignant pheochromocytoma and paraganglioma between March 
2005 and March 2010. The patients comprised 9 males and 6 females, and 
the age range was 37 to 78 years (mean = 57.1 years). Twelve were malignant 
pheochromocytomas and three were malignant paragangliomas (Table 1). In 
all patients, we confirmed MIBG accumulations in the primary or metastatic 
lesions with diagnostic 123I-MIBG scintigraphy before 131I-MIBG therapy. 
 
Low dose diagnostic 123I-MIBG scintigraphy 
We performed 123I-MIBG scintigraphy after intravenous injection of 111MBq 
of 123I-MIBG (FUJIFILM RI Pharma Co., Ltd., Japan), using a dual-head 
gamma camera equipped with a low-medium energy general purpose 
collimator (Toshiba E-CAM, Japan or Siemens Medical Solutions Symbia, 
Germany), specifically designed for reduced the scatter and septal 
penetration of the small fraction of 123I high-energy photons. The activity of 
123I-MIBG was assayed by the supplier to become 111MBq at noon of the 
administration day. In this study, the dose of 123I-MIBG was relatively low 
compared to the standard dose of 123I-MIBG in Western countries, which was 
approved up to 400MBq [13, 21], because only 111MBq of 123I-MIBG had 
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been available for adults due to Japanese regulations until October 2010. 
Whole body scans were obtained at 6 and 24 hours after 123I-MIBG 
administration with 15cm/min of scanning speed on a photo peak of 159keV 
with a 15% window. 
 
131I-MIBG therapy and post-therapeutic scintigraphy 
131I-MIBG therapy was performed 2 to 21 days (mean = 11.9 days) after 
diagnostic 123I-MIBG scintigraphy. To prevent thyroidal uptake of free iodine, 
oral administration of 200mg potassium iodide was commenced one day 
before 131I-MIBG administration and continued for up to 10 days post 
therapy. We intravenously administrated 5.55 to 7.4GBq (mean = 7.28GBq) 
of 131I-MIBG through fixed peripheral venous lines for about an hour using a 
lead-shielded infusion pump with monitoring vital signs for more than 6 
hours from the beginning of 131I-MIBG administration. All patients were 
treated in the isolation room until radiation decreased to less than 30µSv/hr 
at 1m. All therapies were well tolerated. A whole body scan with therapeutic 
dose of 131I-MIBG was obtained once at 2 to 5 days (mean = 3.4 days) after 
injection with 15cm/min of scanning speed on a photo peak of 364keV with a 
15% window, using a high energy collimator. Table 1 shows the dosage and 
the scanning time of 131I-MIBG therapy. 
 
Visual evaluation 
Two experienced nuclear medicine physicians of our institution, who were 
blinded to the findings of the other imaging modalities, evaluated the 
accumulations of 6 and 24-hour images of 123I-MIBG and a post-treatment 
131I-MIBG image. They interpreted all foci except for physiological 
accumulation as abnormal uptake and defined their anatomical location. 
Diffuse accumulation at nasal cavity, salivary glands, thyroid, myocardium, 
liver and bladder were considered as physiological uptake. When small 
lesions or low MIBG uptake lesions are overlapped with physiological (e.g. 
liver) uptake, some lesions might be undetected. When their interpretation 
was discordant, they obtained consensus after conference. To compare the 
lesion detectability of 6 and 24-hour images of 123I-MIBG with a 
post-treatment 131I-MIBG image, we investigated the difference in the 
number of detected lesions in the following 4 sites: bone, lungs, liver and 
others.  
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Quantitative evaluation 
As a quantitative evaluation, we used the uptake ratio. On anterior and 
posterior images at 24 hours of 123I-MIBG, a target region of interest (ROI) 
was set manually by tracing the margin of the most intense lesion and a 
referential ROI and a background (BG) ROI were set on the left thigh and 
the background. The same ROIs were used on each image at 6 hours of 
123I-MIBG and at 3 days of 131I-MIBG. In cases where metastatic lesions 
existed in the left thigh, the right thigh was used as a referential ROI. The 
uptake ratio was calculated with each mean ROI count by the following 
formula: uptake ratio = (target ROI – BG ROI) / (referential ROI – BG ROI). 
We compared the uptake ratios at 6 hours and 24 hours of 123I-MIBG and at 
3 days of 131I-MIBG. To standardize the scanning time, we evaluated 10 
patients whose 131I-MIBG scans were obtained at 3 days after 131I-MIBG 
therapies.  
 
Statistical analysis 
The paired t-test was used for analysis of the sequential changes of the 
uptake ratios between 6 hours and 24 hours after 123I-MIBG injections and 3 
days after 131I-MIBG administrations. A p value of less than 0.05 was 
considered as the significant difference. 
 
Results 
A total of 96 and 106 lesions were identified with 6 and 24-hour images of 
123I-MIBG, respectively. 131I-MIBG post-treatment scans detected 170 lesions. 
Table 2 summarizes visual analyses. In comparison to the 6-hour images of 
123I-MIBG, the 24-hour images of 123I-MIBG could detect more lesions in 8 
(53%) of 15 patients. In all patients, the 6-hour images of 123I-MIBG had no 
advantage compared with the 24-hour images of 123I-MIBG in detecting 
lesions. In comparison between diagnostic 123I-MIBG scans and 
post-treatment 131I-MIBG scans, post-treatment 131I-MIBG scans had better 
lesional detectability than diagnostic 123I-MIBG scans in 8 (53%) of 15 
patients. 123I-MIBG scans were not superior to 131I-MIBG scans in any cases. 
Table 3 shows the number of detected lesions in bone, lungs, liver and others 
with diagnostic 123I-MIBG scans and post-therapeutic 131I-MIBG scans. 
123I-MIBG scans could detect lesions in 56% (64/115) of bone metastases, 64% 
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(9/14) of lung metastases, 88% (15/17) of liver metastases, 75% (18/24) of 
metastases in others, and 62% (106/170) of all lesions compared with 
post-therapeutic 131I-MIBG scans. 
 
Fig. 1 shows time-course changes of uptake ratios in 10 patients whose 
131I-MIBG scans were obtained at 3 days after 131I-MIBG therapies. The 
uptake ratios were higher at later scanning time. There were significant 
differences in the uptake ratios between 6 hours and 24 hours of 123I-MIBG 
(p = 0.031), 6 hours of 123I-MIBG and 3 days of 131I-MIBG (p = 0.020), and 24 
hours of 123I-MIBG and 3 days of 131I-MIBG (p = 0.018). 
 
Fig. 2 and Fig. 3 show the representative scans of 123I-MIBG and 131I-MIBG. 
In Figure 2, the 24-hour image of 123I-MIBG excelled in the lesion 
detectability compared with the 6-hour image of 123I-MIBG. The number of 
lesions between 123I-MIBG and 131I-MIBG was the same. However, the lesion 
was better visualized in the 131I-MIBG image than in the 123I-MIBG image, 
which was confirmed by the quantitative analysis using uptake ratios. 
Figure 3 shows that 131I-MIBG was superior to 123I-MIBG in both visual and 
quantitative assessment. 
 
Discussion 
In this study, we demonstrated with visual and quantitative methods that 
low dose 123I-MIBG (111MBq) scans were not suitable for detecting lesions 
compared with post-treatment 131I-MIBG scans. 
 
Our results were likely due to at least two reasons. Firstly, the diagnostic 
dose of 123I-MIBG was significantly lower compared with the therapeutic 
dose of 131I-MIBG. In the report by Ali et al. [22], the combination of the 
modern gamma camera with a low energy collimator and 123I imaging 
showed a count rate of up to 20-fold greater compared with an equivalent 
activity of 131I, because of the characteristics of 123I and 131I. Therefore, a dose 
of 185MBq 123I was equivalent to almost 3.7GBq 131I in image quality in 
patients with thyroid cancer. Iwano et al. [23] reported that the diagnostic 
scan with 37MBq of 123I was not always predictive of subsequent therapeutic 
131I uptake in detecting residual thyroid tissue and metastases of 
differentiated thyroid cancer. Donahue et al. [24] concluded that 
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post-treatment 131I whole body scans provided incremental clinically 
relevant information in addition to pre-treatment 123I whole body scans in 
10% of patients with differentiated thyroid cancer. Considering the same 
pharmaceutical kinetics of 123I-MIBG and 131I-MIBG, a diagnostic dose of 
123I-MIBG was assumed to be equal in imaging quality to a 20-fold greater 
131I-MIBG dose. In our study, the doses of 123I-MIBG (111MBq) were less 
than one-fiftieth of the doses of 131I-MIBG (5.55 to 7.4GBq). To improve the 
lesion detectability with 123I-MIBG, the dose of 123I-MIBG should be 
increased. Considering that the standard doses of 131I-MIBG therapy for 
malignant pheochromocytoma and paraganglioma are more than 7.4GBq 
[25-27], more than 370MBq of 123I-MIBG might be desirable to detect lesions 
of malignant pheochromocytoma and paraganglioma. 
 
Another likely reason for our results was the difference of scanning time 
after MIBG injections between 123I-MIBG and 131I-MIBG. In this study, the 
24-hour images of 123I-MIBG could detect more lesions than the 6-hour 
images of 123I-MIBG in 8 (53%) of 15 patients. Furthermore, the 2 to 5-day 
images of 131I-MIBG were superior to the 24-hour images of 123I-MIBG in 8 
(53%) of 15 patients. As shown in Figure 1, we demonstrated that the 
lesion-to-referent count ratios increased at later scanning time. These 
results indicated that early scan timing after 123I-MIBG injection was not 
recommended. The European Association of Nuclear Medicine guidelines 
suggest that scanning with 123I-MIBG is performed between 20 and 24 hours 
after injection and selected delayed images (never later than day 2) might be 
useful in the event of equivocal findings on day 1 [13, 28]. In contrast, the 
Japanese Ministry of Health, Labor and Welfare established that 123I-MIBG 
scanning was performed at 24 hours after injection and additional images 
might be obtained at 6 or 48 hours after administration if needed. Our 
results indicated that 6-hour images after 123I-MIBG injection would not be 
necessary. Even if small lesions or low uptake lesions are located in or near 
the kidneys and excretory route that may masked by uptake in these areas, 
6-hour images may not aid the visualization of lesions because physiological 
uptake of MIBG is more intense in early image than late image. 
 
Diagnostic scintigraphy with low dose 123I-MIBG has limitations in detecting 
lesions of malignant pheochromocytoma and malignant paraganglioma. The 
9 
 
possible discrepancy between low dose diagnostic 123I-MIBG and 
post-treatment 131I-MIBG scans should be taken into account when 
developing a treatment plan. An 131I-MIBG post-treatment scan might 
provide us with more clinical information in patients with malignant 
pheochromocytoma and malignant paraganglioma. We recommended that 
patients who had small lesions that were not detected with a low dose 
123I-MIBG scan but confirmed with other imaging modalities, such as CT and 
magnetic resonance imaging, be considered for 131I-MIBG therapy if their 
primary lesion that had been surgically excised had accumulated MIBG. 
 
Our study had some limitations. One limitation was that the dose of 
123I-MIBG of our study was lower than that of the standard dose of 
123I-MIBG in Western countries. Another limitation was that the scanning 
speed of 123I-MIBG scintigraphy was higher than that recommended by 
EANM guidelines (15cm/min compared to the guidance of 5cm/min) [13]. The 
low dose and the fast scanning speed of 123I-MIBG would decrease 
signal-to-noise ratio compared with the high dose and the slow scanning 
speed. Those would result in the reduction of not only the lesional 
decetcability of visual evaluation but the uptake ratio of quantitative 
evaluation of 123I-MIBG scintigraphy. In this study, we did not evaluate the 
detectability of single photon emission computed tomography (SPECT)/CT. 
SPECT/CT is now getting popular as a daily practice. This would certainly 
enhance the detection of the lesion with in the areas of physiological uptake 
(e.g. liver) and the lesion that overlapped on the physiological uptake (e.g. 
bladder) on planar whole-body imaging. 
 
In conclusion, a low dose diagnostic 123I-MIBG scan has limitations 
compared to post-treatment 131I-MIBG scan. Compared with a 24-hour image 
of 123I-MIBG, a 6-hour image of 123I-MIBG has no advantage in detecting 
lesions of malignant pheochromocytoma and malignant paraganglioma. The 
escalation of 123I-MIBG doses might be beneficial for the diagnosis of 
distribution of metastasis. 
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Legends for illustrations 
Fig. 1 Time-course changes of uptake ratios. The uptake ratios are higher at 
later scanning time. Because no abnormal accumulation is detected on the 
6-hour image of 123I-MIBG in patient number 12 in table 1 and table 2, the 
paired t-tests are performed among 9 patients between 6 hours and 24 hours 
of 123I-MIBG and between 6 hours of 123I-MIBG and 3 days of 131I-MIBG and 
among 10 patients between 24 hours of 123I-MIBG and 3 days of 131I-MIBG. 
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Fig. 2 A 37-year-old female with pheochromocytoma, patient number 12 in 
table 1 and table 2. No abnormal accumulation is seen on the 6-hour image of 
123I-MIBG. The 24-hour image of 123I-MIBG can identify a faint accumulation 
in the right mid abdomen and the 3-day image of 131I-MIBG can identify a 
strong accumulation in the same lesion (arrows). No additional uptake is 
detected on the 3-day image of 131I-MIBG. Uptake ratios of the right mid 
abdomen lesion are 3.55 and 5.80 on the 24-hour image of 123I-MIBG and the 
3-day image of 131I-MIBG. The uptake ratio of the 6-hour image of 123I-MIBG 
cannot be calculated because no lesional uptake is detected on the 6-hour 
image of 123I-MIBG. 
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Fig. 3 A 78-year-old female with pheochromocytoma, patient number 3 in 
table 1 and table 2. A total of 7 lesions are detected in the bone with the 6 
and 24-hour images of 123I-MIBG (narrow arrows on each anterior image of 
123I-MIBG). Same lesions are detected (narrow arrows on the anterior image 
of 131I-MIBG) and 7 new lesions can be identified with the 3-day image of 
131I-MIBG (wide arrows on the posterior image of 131I-MIBG). The uptake 
ratios of the lumbar spine (arrow heads on each anterior image of 123I-MIBG 
and 131I-MIBG) are 5.33, 9.21, and 27.07 on each image. 
 
 
 
Tables 
Table 1 Clinical characteristics and protocol of 131I-MIBG therapy 
Patient    
131I-MIBG 
Number Age Sex Diagnosis Dose (GBq) 
Scanning time 
(days) 
1 43 M pheo 7.4 5  
2 46 M para 7.4 5  
3 78 F pheo 7.4 3  
4 76 M pheo 7.4 4  
5 52 M pheo 7.4 5  
6 63 M pheo 7.4 3  
7 45 M pheo 7.4 3  
8 75 M pheo 5.55 2  
9 61 M para 7.4 3  
10 69 M pheo 7.4 3  
11 60 F pheo 7.4 3  
12 37 F pheo 7.4 3  
13 54 F para 7.4 3  
14 39 F pheo 7.4 3  
15 58 F pheo 7.4 3  
MIBG, metaiodobenzylguanidine; pheo, malignant pheochromocytoma; para, 
malignant paraganglioma. 
 
 
 
 
Table 2 The number of lesions on diagnostic 123I-MIBG scans (6 and 24 
hours) and post-treatment 131I-MIBG scans (2 to 5 days) 
Patient 123I-MIBG 131I-MIBG 
Number 6 hours 24 hours 2 to 5 days 
1 9 10  10 
2 5 5  5 
3 7 7  14 
4 10 10  13 
5 1 1  1 
6 3 3  9 
7 5 6  6 
8 3 4  6 
9 23 24  45 
10 1 2  2 
11 6 6  6 
12 0 1  1 
13 1 1  4 
14 6 9  17 
15 16 17  31 
Total 96 106  170 
MIBG, metaiodobenzylguanidine. 
 
 
 
 
 
 
Table 3 The number of detected lesions in bone, lung, liver and others with 
diagnostic 123I-MIBG scans and post-treatment 131I-MIBG scans 
Bone Lung Liver Others Total 
123I-MIBG scan (n) 64 9 15 18 106 
131I-MIBG scan (n) 115 14 17 24 170 
MIBG, metaiodobenzylguanidine. 
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